Company & Sponsor Intelligence
Otsuka Pharmaceutical Co., Ltd.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting0
Completed4
Countries1
Therapeutic footprint
autismdepressionparkinsons
Indexed studies
NCT01617447A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
autism · JapanPHASE3
autism · JapanPHASE3
NCT01617460A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
autism · JapanPHASE3
autism · JapanPHASE3
NCT01634243A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
parkinsons · JapanPHASE2
parkinsons · JapanPHASE2
NCT00882362Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
depression · JapanPHASE3
depression · JapanPHASE3
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →